Table 2.
Univariate and multivariable analyses of prognostic factors for single-agent resistance
| Variable | Rate of single-agent resistance (%) | OR (95% CI)a |
|
|---|---|---|---|
| Univariate | Multivariable | ||
| Age (years) | |||
| <40 | 159/572 (27.8%) | ||
| ≥40 | 34/133 (25.6%) | 0.9 (0.6–1.4) | 0.9 (0.6–1.5) |
| Antecedent pregnancy | |||
| Hydatidiform Mole | 183/677 (27.0%) | ||
| Miscarriage | 4/17 (23.5%) | 0.8 (0.3–2.6) | 0.6 (0.1–2.4) |
| Term | 6/11 (54.5%) | 3.2 (1.0–10.7)a | 3.4 (0.9–12.7) |
| Interval (months) | |||
| <4 | 179/617 (29.0%) | ||
| 4–6 | 9/73 (12.3%) | 0.3 (0.2–0.7)a | 1.1 (0.5–2.7) |
| 7–12 | 5/14 (35.7%) | 1.4 (0.4–4.1) | 4.1 (1.0–16.2)a |
| >12 | 0/1 (0%) | – | – |
| Pre-treatment serum hCG (IU/l) | |||
| <1000 | 19/167 (11.4%) | ||
| 1000–10 000 | 28/187 (15%) | 1.4 (0.7–2.6) | 1.6 (0.8–3.5) |
| 10 000–100 000 | 127/324 (39.2%) | 5.0 (3.0–8.5)a | 5.0 (2.5-10.4)a |
| >100 000 | 19/27 (70.4%) | 18.5 (7.1–48.0)a | 14.3 (4.7-44.1) a |
| Tumor size (cm) | |||
| <3 | 55/302 (18.2%) | ||
| 3–5 | 61/232 (26.3%) | 1.6 (1.1-2.4)a | 0.9 (0.6-1.4) |
| ≥5 | 71/142 (50.0%) | 4.5 (2.9-7.0)a | 2.2 (1.3–3.6)a |
| Number of metastases | |||
| None | 172/644 (26.7%) | ||
| 1–4 | 19/56 (33.9%) | 1.4 (0.8–2.5) | 1.4 (0.7–2.6) |
| 5–8 | 2/4 (50.0%) | 2.7 (0.4–19.6) | 3.5 (0.4–30.4) |
| >8 | 0/0 (0%) | – | – |
a
P < 0.05.